Recent news on Hectorol

DRAXIS Health Reports Results for the First Quarter of 2007  -  May 9, 2007
PR-Inside.com (Pressemitteilung),Dr. Barkin continued, "Although sterile product volumes, including Hectorol(R), were down in the quarter in part because of component delays from a supplier

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  26 Apr 2007
WebWire (press release),Genzyme’s Hectorol® (doxercalciferol) is already indicated for patients with earlier stages of chronic kidney disease, as well as those on dialysis.

American Kidney Fund Launches Medicare Part D Grant Program for ...  -  Apr 3, 2007
PR Web (press release),This program covers common bone disease medications, including Fosrenol®, Hectorol®, Phoslo®, Renagel®, Sensipar® and Zemplar®.

DRAXIS Posts Record Earnings and Cash Flow for 2006  -  Feb 8, 2007
Earthtimes.orgThe increase in the quarter was driven by increased production of Hectorol(R) Injection for Genzyme Corporation (Genzyme) together with increases in

UPDATE 1-TABLE-Draxis Q4 earnings rise, sets 2007 outlook  -  Feb 8, 2007
Reuters...results for 2007 to be weaker compared to the fourth quarter of 2006 mainly due to a delay in receiving component parts related to Hectorol.

Nephrologists Report Practice Pattern Shifts in the Management of ...  -  Feb 1, 2007
PharmaLive.com (press release),In the CKD setting, nephrologists report a growing preference for Abbott's Zemplar capsules, although more than half view the oral forms of Hectorol and

Company with link to Madison gets funding  -  18 Jan 2007
Wisconsin State Journal,Eventually, if the clinical tests prove Cytochroma's drugs are effective and safe, those drugs could be competing against Hectorol, Bone Care's medication.

Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
...markets Renagel® (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, and Hectorol® (doxercalciferol), a ... -WebWire (press release), Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
...markets Renagel(R) (sevelamer hydrochloride), a phosphate binder for patients with end-stage renal disease on hemodialysis, and Hectorol(R) (doxercalciferol ... -Drug Newswire (press release), Genzyme 3rd-Quarter Profit Drops 86% on Acquisitions (Update1)  Oct 12, 2006
...statement. Revenue was $808.6 million, helped by sales from the kidney treatments Renagel and Hectorol, a drug acquired in 2005. ... -Bloomberg Genzyme 3rd-Quarter Profit Drops 86% on Acquisitions (Update4)  Oct 12, 2006
Revenue rose 14 percent to $808.6 million, helped by sales from the kidney treatments Renagel and Hectorol, a drug acquired in 2005. ... -Bloomberg Genzyme, Now In Front For AnorMED, Reports Earnings  Oct 13, 2006
Sales of another kidney drug, Hectorol, increased to $25.5 million. The company's diagnostics and genetics business increased revenue to $89.3 million. ... -BioWorld Online, A 'Drug Deal' Gone Bad for Democrats  Oct 16, 2006
...for 2005, it says Part D will provide Medicare coverage for the first time for "a number of drugs" including its products Renagel and oral Hectorol, which are ... -BBSNews, Baird Sees Genzyme Losing Market Share  Sep 19, 2006
The pressures could impact the company's intermediate-to-longer term growth prospects for Renagel and Hectorol, Genzyme's treatment for secondary ... -MSN Money

UPDATE 1-RESEARCH ALERT-Baird cuts Genzyme to "neutral"  Sep 19, 2006
...through competitive pressure that may impact intermediate-to-longer term growth prospects for both its substantial revenue generating drugs Renagel and Hectorol ... -Reuters

Genzyme downgraded to "neutral"  Sep 19, 2006
Renal Business is facing competitive pressures, which is likely to adversely affect the growth potential of the company's Renagel and Hectorol drugs in the ... -newratings.com

Genzyme initiated with "buy"  Aug 31, 2006
...that the company is well positioned for growth over the forthcoming three years, driven by the performance of Myozyme, Renagel, Fabrazyme, Hectorol, and Synvisc ... -newratings.com

Genzyme sues former Bone Care employees  Aug 9, 2006
BCI, a company that specialized in Vitamin D products, was best known for producing Hectorol, a Vitamin D drug used to treat secondary hyperparathyroidism in ... -WTN News

Ex-Bone Care leaders seek to return  Jul 27, 2006
They are involved in clinical research, quality control, supply chain management and sales of Hectorol, the vitamin D-based drugs Bone Care developed to treat ... -Wisconsin State Journal

Bone Care buyer sues ex-Bone Care executives  Aug 9, 2006
Quinn said that when Genzyme acquired Bone Care it acquired not just its flagship Hectorol drug, but all of the scientific work of Bone Care's employees, "and ... -The Capital Times

Genzyme suing former executives  Aug 10, 2006
Bone Care developed Hectorol, a vitamin D-based drug used to treat a condition that can lead to bone damage in patients with kidney failure. ... -Wisconsin State Journal

American Kidney Fund, Genzyme Announce New Medicare Part D ...  Jul 31, 2006
...when the two organizations launched the Renagel Patient Assistance ProgramSM (RPAP), which provides access to Renagel and Hectorol® (doxercalciferol) for ... -WebWire

Vitamin D just keeps on giving: Local drug firm merges for success  Jul 26, 2006
...sclerosis and secondary hyperparathyroidism. Bone Care's Hectorol drug also treats secondary hyperparathroidism. Cytochroma is focused ... -The Capital Times

Delivers Solid Earnings Growth Based on Strong Top-Line ...  Jul 18, 2006
The expanded US commercial organization is also helping to drive the growth of Hectorol® (doxercalciferol), which treats secondary hyperparathyroidism in ... -Oxfordshire Bioscience Network

US trio takes reins at Cytochroma  Jul 19, 2006
Inc., also of Madison, from a drug developer into an integrated drug company with its own sales force and three formulations of the vitamin D drug Hectorol. ... -Globe and Mail

Genzyme 2nd-qtr earnings rise on higher drug sales  Jul 12, 2006
That sales force was also helping to drive the growth of Hectorol for chronic kidney disease. Sales of Hectorol, which Genzyme acquired ... -Reuters

UPDATE 1-Genzyme 2nd-qtr earnings rise on higher drug sales  Jul 12, 2006
That is also helping to drive the growth of Hectorol, for chronic kidney disease. Sales of Hectorol, which Genzyme acquired last July, were $22.4 million. ... -Reuters

Genzyme shares jump as Q2 earnings top estimates  Jul 12, 2006
That sales force also helped drive the growth of Hectorol for chronic kidney disease. Sales of Hectorol, which Genzyme acquired last July, were $22.4 million. ... -WAVE

Proventiv buyer may have plans in Madison  Jul 9, 2006
Its widely prescribed drug, Hectorol, is used to treat vitamin D deficiencies in patients with kidney disease. Bone Care was sold in July 2005 to Genzyme Corp. ... -Milwaukee Journal Sentinel (subscription)

Genzyme Second-Quarter Profit Gains on Enzyme Therapy Sales  Jul 12, 2006
Genzyme is also benefiting from newer products such as Hectorol, a kidney-disease drug gained through its acquisition last year of Bone Care International Inc. ... -Bloomberg



Genzyme Reports Financial Results for the First Quarter of 2006  Apr 19, 2006
Sales of Fabrazyme(R) (agalsidase beta), Synvisc(R) (hylan GF 20) and Hectorol(R) (doxercalciferol) experienced sequential growth below Genzyme's expectations ... - MSN Money

Genzyme Reports Financial Results for the First Quarter of 2006  Apr 19, 2006
Sales of Fabrazyme® (agalsidase beta), Synvisc® (hylan GF 20) and Hectorol® (doxercalciferol) experienced sequential growth below Genzyme’s expectations ... - WebWire

UPDATE 3-Genzyme profit, sales miss estimates, shares drop  Apr 19, 2006
...sales of Fabrazyme, a treatment for the rare genetic disorder Fabry disease; Synvisc, which treats osteoarthritis of the knee; and Hectorol, for chronic kidney ... - Reuters

UPDATE 4-Genzyme profit, sales miss estimates, shares drop  Apr 19, 2006
...million, but sales of Fabrazyme, a treatment for the rare genetic disorder Fabry disease; Synvisc, for osteoarthritis of the knee; and Hectorol, for chronic ... - Reuters

UPDATE 1-Genzyme 1st-quarter earnings rise on drug sales  Apr 19, 2006
These were Fabrazyme, a treatment for the rare genetic disorder Fabry disease; Synvisc, for osteoarthritis of the knee; and Hectorol, for the treatment for ... - Reuters

DRAXIS Health Reports Results for the First Quarter of 2006  May 11, 2006
...quarter. Full production of sterile liquid injectables, particularly Hectorol® Injection, did not reach normal levels until March. ... - Yahoo! News

Investors Jump Ship at Genzyme  Apr 20, 2006
...last November. The shortfall was blamed on lower-than-expected sales of three of its drugs: Fabrazyme, Synvisc, and Hectorol. The ... - MSNBC

Genzyme "outperform," target price reduced  May 8, 2006
In a research note published this morning, the analysts mention that a recent nephrologist survey indicates that the company’s Renagel and Hectorol drugs are ... - newratings.com

Zacks.com Announces that Nadine Wong Highlights: Amgen, Genentech ...  May 5, 2006
As for Genzyme, its earnings' shortfall was blamed on lower-than-expected sales of three of its drugs: Fabrazyme, Synvisc and Hectorol, and the costs of ... - Business Wire

Genzyme's First-Quarter Sales Below Expectations  Apr 19, 2006
...hoped-for levels were Fabrazyme (agalsidase beta) for Fabry's disease, Synvisc (hylan GF 20) for osteoarthritic knee pain, and Hectorol (doxercalciferol) for ... - BioWorld Online (subscription)

Genzyme's Near-Term Growth Seen Driven By Renagel  Apr 20, 2006
...shortfall was attributed to weaker sales of arthritis drug Synvisc, Fabrazyme, a treatment for a rare disorder known as Fabry disease, and Hectorol, a kidney ... - Forbes





Journal Of Rehabilitation Research And Development: Focus On ...  Mar 28, 2006
The bone mineral density (BMD) of people with spinal cord injury (SCI) increased slightly while taking Hectorol, a synthetic derivative of vitamin D. People ... - Medical News Today



Genzyme Reports Financial Results for Fourth Quarter of 2005 and ...  Feb 15, 2006
...from Avigen Inc., expiring Clolar® inventory acquired from ILEX Oncology Inc., and the turnover of the stepped-up value of Hectorol® inventory acquired from ... - WebWire,

Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue  Jan 9, 2006
Both Renagel and Genzyme's Hectorol(R) (doxercalciferol)are positioned favorably on most of the Part D prescription drug plans now available to Medicare ... - MSN Money

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional